198 related articles for article (PubMed ID: 12204844)
1. Induction of antibodies to viscotoxins A1, A2, A3, and B in tumour patients during therapy with an aqueous mistletoe extract.
Klein R; Classen K; Fischer S; Errenst M; Scheffler A; Stein GM; Scheer R; von Laue HB
Eur J Med Res; 2002 Aug; 7(8):359-67. PubMed ID: 12204844
[TBL] [Abstract][Full Text] [Related]
2. Demonstration of antibodies to the chitin-binding mistletoe lectin (cbML) in tumor patients before and during therapy with an aqueous mistletoe extract.
Klein R; Franz M; Wacker R; Classen K; Scheer R; Von Laue HB; Stoeva S; Voelter W
Eur J Med Res; 2004 Jun; 9(6):316-22. PubMed ID: 15257874
[TBL] [Abstract][Full Text] [Related]
3. In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals.
Klein R; Classen K; Berg PA; Lüdtke R; Werner M; Huber R
Eur J Med Res; 2002 Apr; 7(4):155-63. PubMed ID: 12010650
[TBL] [Abstract][Full Text] [Related]
4. Modulation of cellular and humoral immune responses during exposure of healthy individuals to an aqueous mistletoe extract.
Stein GM; Berg PA
Eur J Med Res; 1998 Jun; 3(6):307-14. PubMed ID: 9620894
[TBL] [Abstract][Full Text] [Related]
5. Cellular immunomodulation and safety of standardized aqueous mistletoe extract PS76A2 in tumor patients treated for 48 weeks.
Dohmen W; Breier M; Mengs U
Anticancer Res; 2004; 24(2C):1231-7. PubMed ID: 15154652
[TBL] [Abstract][Full Text] [Related]
6. Effects of a mistletoe preparation with defined lectin content on chronic hepatitis C: an individually controlled cohort study.
Huber R; Lüdtke R; Klassen M; Müller-Buscher G; Wolff-Vorbeck G; Scheer R
Eur J Med Res; 2001 Sep; 6(9):399-405. PubMed ID: 11669085
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the cellular and humoral immune responses of tumor patients by mistletoe therapy.
Stein G; Henn W; von Laue H; Berg P
Eur J Med Res; 1998 Apr; 3(4):194-202. PubMed ID: 9533928
[TBL] [Abstract][Full Text] [Related]
8. Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrolective cohort study.
Schumacher K; Schneider B; Reich G; Stiefel T; Stoll G; Bock PR; Hanisch J; Beuth J
Anticancer Res; 2003; 23(6D):5081-7. PubMed ID: 14981970
[TBL] [Abstract][Full Text] [Related]
9. [Value of mistletoe lectin standardized mistletoe extract for evaluating antitumor properties].
Mengs U; Witthohn K; Schwarz T; Lentzen H
Wien Med Wochenschr; 1999; 149(8-10):262-4. PubMed ID: 10483695
[TBL] [Abstract][Full Text] [Related]
10. Generation of reactive oxygen intermediates (ROI) by the thionins from Viscum album L.
Büssing A; Schaller G; Pfüller U
Anticancer Res; 1998; 18(6A):4291-6. PubMed ID: 9891480
[TBL] [Abstract][Full Text] [Related]
11. Thionins from Viscum album L: influence of the viscotoxins on the activation of granulocytes.
Stein GM; Schaller G; Pfüller U; Schietzel M; Büssing A
Anticancer Res; 1999; 19(2A):1037-42. PubMed ID: 10368652
[TBL] [Abstract][Full Text] [Related]
12. [The mistletoe myth--claims, reality and provable perspectives].
Gabius HJ; André S; Kaltner H; Siebert HC; von der Lieth CW; Gabius S
Z Arztl Fortbild (Jena); 1996 Apr; 90(2):103-10. PubMed ID: 8686332
[TBL] [Abstract][Full Text] [Related]
13. Viscotoxin-free aqueous extracts from European mistletoe (Viscum album L.) stimulate activity of human granulocytes.
Stein GM; Pfüller U; Schietzel M
Anticancer Res; 1999; 19(4B):2925-8. PubMed ID: 10652574
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of immunological reactivity of patients with adverse effects during therapy with an aqueous mistletoe extract.
Stein GM; Berg PA
Eur J Med Res; 1999 May; 4(5):169-77. PubMed ID: 10336405
[TBL] [Abstract][Full Text] [Related]
15. Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract.
Heiny BM; Albrecht V; Beuth J
Anticancer Res; 1998; 18(1B):583-6. PubMed ID: 9568181
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic activity and absence of tumor growth stimulation of standardized mistletoe extracts in human tumor models in vitro.
Kelter G; Schierholz JM; Fischer IU; Fiebig HH
Anticancer Res; 2007; 27(1A):223-33. PubMed ID: 17352237
[TBL] [Abstract][Full Text] [Related]
17. Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from Viscum album L. and neutralize lectin-induced cytotoxicity in vitro.
Stettin A; Schultze JL; Stechemesser E; Berg PA
Klin Wochenschr; 1990 Sep; 68(18):896-900. PubMed ID: 2124308
[TBL] [Abstract][Full Text] [Related]
18. [Lectin-related use of mistletoe: an experimental form of treatment with preclinically demonstrated potential risks].
Gabius S; Gabius HJ
Dtsch Med Wochenschr; 2002 Mar; 127(9):457-9. PubMed ID: 11870561
[No Abstract] [Full Text] [Related]
19. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial.
Friess H; Beger HG; Kunz J; Funk N; Schilling M; Büchler MW
Anticancer Res; 1996; 16(2):915-20. PubMed ID: 8687151
[TBL] [Abstract][Full Text] [Related]
20. Mistletoe (viscum album) lectins as cytokine inducers and immunoadjuvant in tumor therapy. A review.
Bocci V
J Biol Regul Homeost Agents; 1993; 7(1):1-6. PubMed ID: 8346712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
